BIOADAPTIVES (BDPT) Stock News, Jun 2022-Apr 2023

BioAdaptives, Inc. (OTCMkts: BDPT) has appointed Dr. Yaguang Liu to its Board of Directors, enhancing its leadership in research and development of natural medicines. CEO Edward Jacobs expressed optimism about Dr. Liu's patents and expertise, anticipating his guidance will be pivotal for the company's expansion into global markets. Dr. Liu, founder of L.Y. Research Corporation, holds 32 U.S. patents for natural botanicals used in treating various diseases and has significant experience with the FDA and clinical studies. BioAdaptives focuses on natural products aimed at improving health and wellness for humans and animals, with promising plans for product expansion.

BioAdaptives, Inc. (OTCMkts: BDPT) announced on March 30, 2023, a second non-exclusive license agreement with LY Research Corporation to market a patented eye health product aimed at myopia and presbyopia. This product utilizes a patented liposome and polymeric micelles formulation to enhance lutein solubility. The global market for myopia and presbyopia treatments was valued at USD 16.47 billion in 2021, growing at a CAGR of 8.5% through 2030, with significant demand due to rising vision impairment cases. Patent # US 9,622,970 B2 is valued at approximately USD 570 million, highlighting its potential market impact.

BioAdaptives, Inc. (OTCMkts: BDPT) has signed a non-exclusive license agreement with LY Research Corporation to market a patented glucose management product (Patent # US 8,114,444 B2), valued at $210 million. This partnership aims to capitalize on the growing diabetes supplement market, projected to reach $31.42 billion by 2030, with a CAGR of 10.3% from 2022-2030. The product, Glucobotanic, contains compounds that help regulate blood glucose levels and may inhibit sugar conversion to fat. BioAdaptives focuses on natural plant- and algal-based health products, currently serving over 13,000 shareholders.

BioAdaptives, Inc. (BDPT) has signed a Letter of Intent with World Wellness, LLC to develop a comprehensive weight management system utilizing the patented FIT YOUR OUTFIT (FYO) app. This innovative app leverages AI to measure body composition accurately through a single photo, matching the precision of the DXA method. The collaboration aims to introduce new health and wellness products and tap into a market projected to reach $1.4 billion by 2027 and $2.6 billion by 2030. Leading wellness expert Dr. David Allen is involved in the project, emphasizing the importance of body fat percentage as a health indicator.

BioAdaptives, Inc (OTC BDPT) has announced the launch of a Wholesale Division to broaden its product sales beyond online channels. This decision comes in response to high demand from affiliate members and retail stores seeking to diversify their offerings. The global dietary supplements market, valued at USD 151.9 billion in 2021, is projected to grow at a CAGR of 8.9% from 2022 to 2030. The company's focus includes developing custom natural supplement formulations and expanding product availability, responding to the growing market interest.

BioAdaptives Inc. (OTCMkts: BDPT) announces the launch of MindnMemory, a nootropic aimed at enhancing memory, focus, and mental clarity, particularly benefiting seniors and e-Gamers. This stimulant-free formulation is rooted in Traditional Chinese Medicine and aims to avoid the sudden highs and crashes typical of caffeine. The global nootropic market surpassed $10.5 billion in 2021 and is projected to hit $31 billion by 2029, growing at 18% annually. CEO Edward Jacobs highlights that MindnMemory promotes sustained mental performance through increased mitochondrial energy production.

BioAdaptives, Inc. (OTCMkts: BDPT) has launched a new line of enhanced nutraceuticals for holistic healthcare practitioners, targeting symptoms associated with COVID-19 aftermath like brain fog and fatigue. The U.S. alternative medicine market is valued at approximately $21 billion, serving over one million healthcare professionals. CEO Dr. Edward Jacobs highlighted the products' neuro-protective, anti-viral, and calming properties. While the current product lineup includes popular items like PluriPain® and PrimiSleep™, new “Nu” branded offerings aim to meet increasing practitioner demand. None of the claims have FDA approval.

BioAdaptives, Inc. (OTCMkts: BDPT) has launched PrimiSleep™, a natural sleep supplement developed to promote relaxation and uninterrupted sleep without cognitive impairment. The product is based on Traditional Chinese Medicine and Ayurvedic principles, addressing the increasing demand for effective sleep solutions, particularly as chronic sleep issues affect over 70 million Americans. The global sleeping aids market is projected to grow from $64 billion in 2021 to $118 billion by 2030, with a CAGR of 7.1%. CEO Edward Jacobs highlights the importance of optimal sleep for overall health.

BioAdaptives, Inc. (OTCMkts: BDPT) has introduced a cost-effective wellness combination package featuring PluriPain®, PrimiLungs™, and PrimiSleep™ to address increased consumer demand for solutions to chronic symptoms. These products may help manage issues like brain fog, pain, and sleep disturbances, particularly in those affected by COVID-19. Each formula is designed to provide specific benefits, and together they are reported to enhance well-being. The introductory package is available for a nominal fee, allowing consumers to experience the synergistic effects firsthand.